Going for the golden mean: Now is an exciting time to have a diverse biotech portfolio

Healthcare innovations worth taking a shot at

The general public's knowledge of biotech has increased and improved exponentially following the pandemic. That is perhaps one of the positives we can take from Covid-19: Pfizer, Moderna, BionTech and AstraZeneca are all now household names.

Just as the public's knowledge has improved, so too have investors woken up to the opportunities and possibilities investing in biotechnology could bring. Before Covid-19 put a petri-dish around the globe, the biotechnology industry was benefitting from increasing global population growth and the inexorable growth of the middle class in developing countries. Life expectancy was also increasing worldwide. However, we have to be careful what we wish for: in the era of the "I", the selfie and the global desire for a lifestyle of instant gratification, that too leads to a concerning incre...